14.12.2012 • News

AkzoNobel to Divest Its North American Decorative Paints Business

AkzoNobel today announced the divestment of its North American Decorative Paints business to PPG Industries, for the value of $1.05 billion. In 2011, the North American Decorative Paints business had revenues of $1.5 billion, around 7% of AkzoNobel's total 2011 revenue.

AkzoNobel continues to have a strong presence in North America through its Performance Coatings and Specialty Chemicals businesses, with combined 2011 revenues of over $2.7 billion and close to 5,000 employees.

The company made the decision to divest Decorative Paints North America following a successful four year turnaround. AkzoNobel has made the strategic choice to focus its Decorative Paints Business Area on key markets in Europe and its strong positions in high growth regions.

The cash proceeds of approximately $875 million will be deployed to support the company's strategy. This includes investing in organic growth for AkzoNobel, and reducing net debt. More details on AkzoNobel's priorities will be disclosed during the Strategy Update on February 20, 2013.

AkzoNobel Decorative Paints in North America has around 5,000 employees and operates 8 manufacturing sites. It has a number of successful brands, including Glidden in the US and Sico in Canada.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read